trending Market Intelligence /marketintelligence/en/news-insights/trending/f13szcvvsqiqdmbaaz-xcw2 content esgSubNav
In This List

BioSig implementing 1-for-2.5 reverse stock split for Nasdaq uplisting

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


BioSig implementing 1-for-2.5 reverse stock split for Nasdaq uplisting

BioSig Technologies Inc. said it will implement a 1-for-2.5 reverse split of its common stock after the close of business Sept. 10 to meet requirements for its Nasdaq uplisting.

The Los Angeles-based development stage medical device company said its stock will begin trading on a split-adjusted basis from Sept. 11.

The reverse split was approved by BioSig's stockholders July 30.

BioSig's first product, the PURE EP System, which records and calculates electrocardiographic and intracardiac signals, among other things, for patients undergoing electrophysiology procedures in a laboratory, was approved by the U.S. Food and Drug Administration in August.